Overview

Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 82 patients who have their skin cancer surgically removed resulting in the need of a full-thickness skin graft. The objective of this randomized safety study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in full-thickness skin grafts compared to standard of care.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Petrolatum
Timolol